FDA heightens warning for Paxil

From the Edmonton Sun:
The U.S. Food and Drug Administration is strengthening its warning that the antidepressant Paxil may be associated with birth defects, citing a new study that found babies born to women taking the drug had double the rate of heart defects of other infants.

The FDA announced yesterday it has asked manufacturer GlaxoSmithKline to reclassify the drug, which goes by the generic name paroxetine, as a "Category D" drug for pregnant women. The classification means that studies in pregnant women have shown a risk to the fetus. ...more